After hours:
Chart Events
Performance Outlook
| Previous Close | 1.5100 |
| Open | 1.5600 |
| Bid | 1.5500 x 800 |
| Ask | 1.6700 x 1300 |
| Day's Range | 1.5000 - 1.6456 |
| 52 Week Range | 1.0500 - 4.0380 |
| Volume | |
| Avg. Volume | 140,326 |
| Market Cap | 76.016M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RNLX
Related Research
- Renalytix plcWD: Raising target price to $82.00WALKER & DUNLOP INC has an Investment Rating of HOLD; a target price of $82.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.RatingFair ValueEconomic Moat4 months agoArgus Research
GlobeNewswireRenalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To
- GlobeNewswire
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales EffortLONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the appointment of Howard Doran as Chief Business Officer, effective September 1, 2023. Mr. Doran’s primary resp
- GlobeNewswire
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney diseaseLONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces the launch of its Clinical Advisory Board, a world-leading, multi-disciplinary clinical group, to help advance the use of FDA authorized kidneyintelX.dkd™ in mitigating uncontrolled kidney disease progression and guiding ea
